We're back for what we're hoping to be another good week for stocks. The S&P 500 has once again found itself in new high territory and it sure doesn't look like the strength in stocks is stopping anytime soon. Of course anything is possible I suppose, but what's going to stop the markets from screaming higher? North Korea couldn't do it. Wall Street has come to accept slow growth. No matter how bad the weather has been in certain parts of the country, that hasn't seem to create cause for pause. Earnings continue to grow. The dollar doesn't seem to matter. The list goes on, but the markets still manage to find new highs. That's just the way the markets behave when they're in blue sky territory. In other words, there's literally nothing that can stop them until some sort of economic black swan surfaces, or a major geopolitical shoe drops, and clearly neither of those have come to fruition yet. Although our most recent newly featured stock in LottoGopher Holdings, Inc. (LTTGF) has had a bit of a rough time out of the gate, that's just the nature of penny stocks. You never really know when they're going to start making their biggest moves up the charts, but one thing is for sure - if the company can deliver on the revenue and earnings front as they move forward, we could end up looking back at $.20 cents as a gift. We've seen it before and I'm sure we'll see it again, so it's just going to require some patience before we'll know if the stock and the company are seriously going to disrupt the lotto industry online. I suspect they will, because there's just way too many smart names involved in this particular deal. Additionally, on Friday NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company, announced the publication of an editorial featuring LottoGopher Holdings (OTCQB: LTTGF) (CSE: LOTO) (FRANKFURT: 2LG), a client of NNW and lottery messenger service that provides its subscribers with the security of ordering and managing the legal purchase of state lottery tickets online using debit and credit cards. The publication is titled, "Industry Leaders Find Success in Subscription-Based Business." It discusses multiple companies with winning strategies in the subscription business. To view the full publication, visit: https://www.networknewswire.com/industry-leaders-find-success-subscription-based-business/ "As a lottery messenger service cognizant of consumer demand for convenience, LottoGopher Holdings (LTTGF) enables people to buy lottery tickets legally in California, at the same price as at a store, with a debit or credit card. Featured on NBC, CNN, CBS News, ABC and Fox News, and in Forbes, Time and the Los Angeles Times, the company is an increasingly recognizable brand. The company's success and anticipated growth are anchored to the conveniences that it offers to subscribers. LottoGopher subscribers maintain an account balance, which is updated after each drawing, while the system secures tickets directly from the lottery retailer. "The emerging company has seen positive signs during its testing period. Among visitors to the site, 7 percent provided their email address, 43 percent of those who signed up via email became members, and 12 percent of freemium plan members converted to paid memberships. The company's goal is to create a subscriber base of approximately half a million paying members by 2020 in an effort to achieve nearly $50 million in annual revenues -- a mission that accompanies its plan to expand its reach into 22 other states." As you can see, we're not the only ones convinced LottoGopher has some serious potential. As a matter of fact, if you start doing some digging, you'll find there's an awful lot of folks out there who think the same thing. Just remember, the best time to buy the right penny stocks is when nobody wants them. Small and micro cap stocks can obviously be a fickle bunch, but I sure hope all of you participated in Abeona Therapeutics Inc. (ABEO) back when we first put the idea out there in early June. What a tremendous stock this has been for all of us, and it's not like this happens all of the time. We put the speculative biotech out there back in early June when the stock was hovering around $5 bucks or so. The company focuses on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases. The company's lead programs are ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B; and ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A. Considering small biotech stocks are so volatile though, if you haven't already, it's probably a great time to take the profits and move on. You can see the stock had a tremendous day on Friday, but we'd hate to see investors continue to hang on to the stock, only to have it do a 180, otherwise known as a return back to $5 bucks. Trust me, I've seen this so many times before where investors get too greedy, so if it were up to me, I'd lock in those profits and wait for another opportunity in another potentially promising stock.